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Abstract. Recent studies have shown anticancer activity of 
apigenin by suppressing glucose transporter 1 (GLUT1) expres-
sion in cultured cancer cells; however, it is not clear whether 
apigenin can suppress glucose metabolism in lung cancer cells 
or sensitize them to inhibition of glutamine utilization-mediated 
apoptosis through metabolic and oxidative stress. We show that 
apigenin significantly decreases GLUT1 expression in mice. 
Furthermore, we demonstrate that apigenin induces growth 
retardation and apoptosis through metabolic and oxidative stress 
caused by suppression of glucose utilization in lung cancer cells. 
The underlying mechanisms were defined that the anticancer 
effects of apigenin were reversed by ectopic GLUT1 overexpres-
sion and galactose supplementation, through activation of pentose 
phosphate pathway-mediated NADPH generation. Importantly, 
we showed that severe metabolic stress using a glutaminase 
inhibitor, compound 968, was involved in the mechanism of 
sensitization by apigenin. Taken together, the combination of 
apigenin with inhibitors of glutamine metabolism may provide a 
promising therapeutic strategy for cancer treatment.
Introduction
The flavone apigenin (4',5,7,-trihydroxyflavone), is a plant 
secondary metabolite that occurs widely in numerous fruits. 
It is a potent anticancer drug that can suppress cancer growth, 
angiogenesis, and metastasis in multiple types of cancer (1). 
Mechanistically, several studies have shown that apigenin 
suppresses the activation of nuclear transcription factor-κB 
(NF-κB), phosphoinositide 3-kinase (PI3K), epidermal 
growth factor receptor (EGFR), hypoxia-inducible factor-1α 
(HIF-1α), vascular endothelial growth factor (VEGF), 
cyclin D1, and vascular cell adhesion molecule 1 (VCAM-1), 
which play critical roles in the regulation of cell growth, cell 
cycle, angiogenesis, metastasis, and apoptosis (2). In addition, 
several studies have shown that apigenin causes accumulation 
of intracellular reactive oxygen species (ROS) and oxidative 
stress through the depletion of cellular glutathione (GSH), 
an important factor in redox balance (3-6). Nevertheless, the 
precise molecular mechanism by which decreased cellular 
GSH levels and increased levels of ROS relate to apigenin-
mediated apoptosis is not fully understood.
Cancer cells use large amounts of glucose and glutamine 
to meet the increased energetic and anabolic demands associ-
ated with unlimited cell growth and survival (7-9). Increased 
glucose utilization in cancer cells is achieved primarily 
by upregulation of the expression of glucose transporter 1 
(GLUT1), which is widely expressed in many tumors, including 
hepatic, pancreatic, breast, brain, lung, colorectal, and 
cervical cancers (10). Indeed, several reports have shown that 
GLUT1 inhibitors, such as fasentin, phloretin, and WZB117, 
suppress growth and induce cell death in cancer cells (11-13). 
Upregulation of GLUT1 expression is closely associated 
with chemoresistance, tumor aggressiveness, and decreased 
survival among patients (14,15). Therefore, downregulation of 
GLUT1 expression could be a promising therapeutic strategy 
for cancer treatment.
The pentose phosphate pathway (PPP), which is required 
for biosynthesis of ribonucleotides and NADPH, can be initi-
ated by glucose-6-phosphate generated by hexokinase as an 
initial key enzyme in glucose metabolism (16). As a cellular 
reducing power, NADPH can remove ROS through regula-
tion of the GSH and thioredoxin (TRX) systems that directly 
scavenge ROS and repair ROS-induced cellular damage (7). 
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Thus, inhibition of NADPH production has been proposed as 
a clinical intervention for cancer treatment. Indeed, preclinical 
studies have shown that inhibition of glucose-6-phosphate 
dehydrogenase (G6PD), an enzyme that initiates the PPP, is 
sufficient to decrease cell growth in leukemia, glioblastoma, 
and lung cancer cells (17).
Glutamine is a critical energy source required to main-
tain cell growth and survival. Growing cancer cells are 
commonly dependent upon a supply of glutamine to support 
the tricarboxylic acid (TCA) cycle. Mechanistically, gluta-
mine can be converted to glutamate and α-ketoglutarate 
(α-KG) via the enzymes glutaminase (GLS) and gluta-
mate dehydrogenase (GDH) (18). Previous studies have 
shown that inhibition of glutamine metabolism by GLS 
inhibitors, including 6-diazo-5-oxo-L-norleucine (DON), 
Bis-2-[5-phenylacetamido-1,2,4-thiadiazol-2-yl] ethyl sulfide 
(BPTES), and compound 968, or genetic targeting of 
GLS or GDH using small interfering RNA (siRNA), can 
suppress cell viability and increase apoptosis in cancer cells. 
This suggests that inhibition of glutamine utilization might 
cause cancer cells to become more sensitive to the effects 
of conventional anticancer drugs (18-20). However, there is 
no available information addressing synergistic effects of 
apigenin on targeting cancer specific metabolism, such as 
glutamine metabolism.
In this study, we examined whether apigenin: i) inhibits 
GLUT1 expression and glucose utilization, thereby suppressing 
cell growth and inducing apoptosis; ii) downregulates NADPH 
and GSH production by inhibition of glucose metabolism, 
thereby resulting in increased oxidative stress; and iii) sensi-
tizes lung cancer cells to inhibition of glutamine utilization, 
thereby causing apoptosis and growth retardation.
Materials and methods
Reagents and antibodies. N-acetyl-L-cysteine (NAC), apigenin, 
2'-7'-dichlorodihydrofluorescein diacetate (DCF-DA) and 
compound 968 were purchased from Sigma-Aldrich (St. Louis, 
MO, USA) or Millipore (Billerica, MA, USA). Antibodies 
recognizing cleaved caspase-9, cleaved caspase-3, PARP, and 
HK1 (catalog nos. 9502, 9661, 9546, and 2024, respectively) 
were purchased from Cell Signaling Technology (Danvers, 
MA, USA). GLUT1 (sc-7903), GLS1 (156876) and β-tubulin 
(sc-9104) were purchased from Santa Cruz Biotechnology 
(Dallas, TX, USA) and Abcam (Cambridge, MA, USA).
Cell culture, plasmids, shRNA, and generation of stable cell 
lines. Lung cancer cells were cultured in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 10% fetal bovine 
serum and 25 mM glucose. The lentiviral vector pLenti-GIII-
CMV-SLC2A1, expressing human GLUT1 was obtained from 
Applied Biological Materials Inc. (Richmond, BC, Canada). A 
short hairpin RNA construct targeting GLS1 was purchased 
from Sigma-Aldrich. The hairpin sequence was: 5'-CCGGG 
CCCTGAAGCAGTTCGAAATACTCGAGTATTTCGAAC 
TGCTTCAGGGCTTTTTG-3'. Lentiviral particles were 
produced in HEK293T cells, harvested 48 h after transfection, 
and then used to infect lung cancer cells. Infected lung cancer 
cells were selected by growth on media containing 2 µg/ml of 
puromycin (Invitrogen, Carlsbad, CA, USA) for 6 days.
Western blotting. Cells were lysed in buffer containing 
1% IGEPAL, 150 mM NaCl, 50 mM Tris-HCl (pH 7.9), 10 mM 
NaF, 0.1 mM EDTA, and protease inhibitor cocktail. Protein 
samples were separated by SDS-PAGE, and the separated 
proteins were then transferred to a PVDF membrane (Millipore). 
Membranes were incubated in the presence of primary antibodies 
(1:1,000) at 4˚C overnight, and HRP-conjugated secondary anti-
bodies (1:10,000) were incubated for 1 h at room temperature. 
Proteins were visualized using an enhanced chemiluminescence 
(ECL) Prime kit (GE Healthcare, Pittsburgh, PA, USA).
ROS measurement. To measure ROS levels, cells were incu-
bated with Hank's balanced salt solution (HBSS), containing 
30 µM DCF-DA, for 30 min. After incubation, cells were 
detached and resuspended in phosphate-buffered saline (PBS) 
in preparation for fluorescence-activated cell sorting (FACS) 
analysis.
RNA isolation and RT-qPCR. Total RNA was extracted from 
cells using TRIzol (Invitrogen), and 2 µg of total RNA was 
used for cDNA synthesis using a high capacity cDNA reverse 
transcription kit (Applied Biosystems). Quantitative PCR was 
performed using SYBR Green PCR Master Mix (Applied 
Biosystems). The sequences of the PCR primers (5'-3') were: 
GAGAGTTTCATCGGAGAGCC and CAGCGAGAATCGG 
CTACAG for HK1; GGCATTGATGACTCCAGTGTT and 
ATGGAGCCCAGCAGCAA for GLUT1; CTTGGGACAG 
CAGCCTTAAT and CAAGCTGGACGTTAAAGGGA for 
PGK1; AGCCCTTTCTCCATCTCCTT and AACCATGAC 
CAAGTGCAGAA for HK2; TACAGGCACAGTCGCAG 
AGT and CACTTCCTGGATGCTTGCTG for ALDOA; 
CCTGGCATGGATCTTGAGAA and TACGTTCACCT 
CGGTGTCTG for ENO1.
Glucose consumption, ATP, and lactate production assays. As 
previously described (9), lactate and glucose levels in cultured 
media were measured using lactate colorimetric assay kit and 
glucose colorimetric assay kit, respectively (BioVision, USA). 
Briefly, cells were cultured in DMEM without phenol red for 
24 h, and then cultured media were mixed with assay solu-
tion. To measure intracellular ATP levels, cells were cultured 
in 6-well plates, and cell lysates were mixed with reaction 
buffer. ATP levels in the cell lysates were then determined 
using a luciferin-luciferase-based assay kit (Invitrogen), used 
according to the manufacturer's instructions. All values were 
normalized relative to cellular protein concentration.
Glutathione and NADPH assays. To prepare samples for 
determination of glutathione levels, cells were cultured 
in 6-well tissue culture dishes, and then cell lysates were 
obtained in extraction buffer without dithiothreitol (DTT) or 
β-mercaptoethanol. The levels of reduced glutathione (GSH) 
and oxidized glutathione (GSSG) were measured using a 
Glutathione Colorimetric Detection kit (BioVision) and an 
OxiSelect Glutathione Assay kit (Cell Biolabs), respectively, 
as previously described (21). The levels of NADPH in 
cultured cells were measured using a NADPH quantitation 
kit (BioVision). Briefly, cell lysates were extracted in NADPH 
extraction buffer, and then NADPH levels were determined by 
measurement of absorption at a wavelength of 450 nm.
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Clonogenic cell survival assays. To measure clonogenic cell 
survival, 1x104 lung cancer cells were seeded in 6-well tissue 
culture dishes, and incubated for 7 days. After incubation, cells 
were fixed in 10% paraformaldehyde, and then stained with 
crystal violet for 10 min.
Apoptosis assays. A kit utilizing Annexin V-FITC and prop-
idium iodide (BD Biosciences, San Jose, CA, USA) was used 
to quantify the numbers of apoptotic cells. Briefly, cells were 
detached from the culture dishes, washed with cold PBS, 
and then incubated with anti-Annexin V-FITC antibody and 
propidium iodide. Apoptotic cell numbers were determined by 
FACS analysis.
Statistical analysis. All data were analyzed using the unpaired 
Student's t-test for two experimental comparisons and one-way 
ANOVA with Tukey post-test for multiple comparisons. Data 
are represented as means ± standard deviations (SD). A p-value 
<0.05 was considered statistically significant.
Results
Apigenin reduces GLUT1 expression levels. Because it 
has been reported that apigenin exerts an anticancer effect 
through suppression of GLUT1 expression (22-25), we exam-
ined whether apigenin also downregulates gene expression 
related to glycolysis, including GLUT1, HK1, PGK1, HK2, 
ALDOA, and ENO1. The results were consistent with those of 
previous reports (22-25) that apigenin significantly decreased 
GLUT1 mRNA (Fig. 1A) and protein (Fig. 1B) levels, but did 
not decrease the levels of other glycolytic enzymes in H1299 
or H460 lung carcinoma cells. In addition, GLUT1 mRNA 
levels were also decreased by apigenin treatment in other 
cancer cell lines, including A549 (lung carcinoma), H460 
(lung carcinoma), H2030 (lung adenocarcinoma), HCT116 
(colorectal carcinoma), SW480 (colorectal adenocarcinoma), 
and A375 (melanoma) (Fig. 1C). To elucidate whether apigenin 
suppresses GLUT1 expression in mice, we measured GLUT1 
and GLUT4 expression levels in skeletal muscle, white adipose 
tissue, the heart, brain, liver, lung, and pancreas obtained 
from apigenin-treated mice. Fig. 1D shows that apigenin 
significantly suppressed GLUT1 but not GLUT4 expression 
in the brain, liver, lung, and pancreas. These results indicate 
that apigenin decreases GLUT1 mRNA and protein levels in 
various human cancer cell lines, and in mice. All experiments 
were performed according to the guidelines of the Animal 
Care and Use Committee, Konkuk University, Korea.
Apigenin causes cellular metabolic and oxidative stress. 
Cancer cells use large amounts of glucose to generate glyco-
lytic intermediates and end products, including lactate, ATP, 
nucleotides, lipids, amino acids, and NADPH, all of which 
contribute to rapid cell proliferation (8). Therefore, we investi-
gated whether apigenin can block glucose utilization in cancer 
cells. Interestingly, glucose consumption, lactate production, 
and ATP production were all strongly decreased by apigenin 
Figure 1. Apigenin decreases GLUT1 mRNA and protein levels in several cancer cell lines. (A) H1299 (lung carcinoma) cells were incubated in the absence or 
presence of 10 µM apigenin for 24 h, and then glycolytic gene expression levels were assessed by quantitative RT-PCR. Values represent mean ± SD of three 
independent experiments performed in triplicate; *p<0.05. (B) GLUT1 protein levels were determined by immunoblotting (n=3) and quantified by ImageJ. 
(C) GLUT1 mRNA levels were measured by quantitative RT-PCR in A549 (lung carcinoma), H460 (lung carcinoma), H2030 (lung adenocarcinoma), HCT116 
(colorectal carcinoma), SW480 (colorectal adenocarcinoma), and A375 (melanoma). (D) Mice were injected daily with apigenin (1 mg/kg) or DMSO for 
10 days. GLUT1 and GLUT4 mRNA levels in the liver, lung, brain, pancreas, skeletal muscle, white adipose, and heart were measured by quantitative RT-PCR. 
Values represent mean ± SD (n=6); *p<0.05.
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treatment (Fig. 2A). Glucose-6-phosphate, which is produced 
from glucose, can be shunted into the oxidative branch of the 
PPP by glucose-6-phosphate dehydrogenase, thereby gener-
ating NADPH and promoting redox homeostasis (26,27). Here, 
we demonstrated that NADPH generation by the oxidative 
branch of the PPP is decreased by apigenin treatment. Fig. 2B 
shows that, in apigenin-treated lung cancer cells, NADPH and 
GSH levels were significantly decreased, whereas GSSG levels 
were increased. Since NADPH maintains redox homeostasis 
through generation of GSH, which is necessary for the elimi-
nation of hydrogen peroxide (H2O2) by glutathione peroxidase 
(GPx) (27), we measured intracellular ROS levels. As we had 
hypothesized, intracellular ROS levels were strongly increased 
in apigenin-treated H1299 cells (Fig. 2C). Fig. 2D shows 
significantly decreased NADPH levels in the brain, liver, lung, 
and pancreatic tissues derived from apigenin-treated mice. 
These results suggest that apigenin induces oxidative stress 
through destruction of glucose utilization-mediated redox 
homeostasis.
Apigenin causes oxidative stress leading to apoptosis. Because 
apoptotic signal transduction cascades involving caspase-9, -3 
and PARP cleavage can be activated by increased ROS levels 
(9,28), we examined whether apigenin could likewise increase 
apoptosis through this pathway. Fig. 3A shows that apoptotic 
cell numbers were increased by ~30% in apigenin-treated 
H1299, H460, and H2030 lung cancer cells. Furthermore, in 
H1299 and H460 cells, apigenin increased caspase-9, -3 and 
Figure 2. Apigenin suppresses aerobic glycolysis and induces oxidative stress. (A) Glucose consumption, lactate production, and ATP production were mea-
sured in lung cancer cell lines treated with 10 µM apigenin. Values represent mean ± SD of three independent experiments performed in duplicate; *p<0.05. 
(B) Intracellular NADPH, GSSG, and GSH levels were measured in lung cancer cell lines treated with 10 µM of apigenin. Values represent mean ± SD of 
three independent experiments performed in duplicate; *p<0.05. (C) Intracellular ROS levels were measured using the oxidation-sensitive probe, DCF-DA, in 
H1299 lung cancer cells treated with 10 µM apigenin. (D) NADPH levels in tissues from mice introduced with 1 mg/kg apigenin. Values represent mean ± SD 
(n=6); *p<0.05.
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PARP cleavage in a dose-dependent manner (Fig. 3B). In addi-
tion, apigenin-induced apoptosis may be mediated by elevated 
ROS levels in H1299 and H460 cells, because treatment with 
the antioxidant, N-acetyl-L-cysteine (NAC), significantly 
rescued cell viability (Fig. 3C), and suppressed cell apoptosis 
(Fig. 3D). Taken together, these results show that accumulation 
of ROS mediates apigenin-induced apoptosis.
Galactose supplementation confers resistance to apigenin-
induced apoptosis by re-activating antioxidant capacity. 
Because galactose supports NADPH production and cancer 
cell proliferation largely through its metabolism in the pentose 
phosphate pathway (26,29), we examined whether galactose 
supplementation could attenuate apigenin-mediated oxidative 
stress. Interestingly, the decreased levels of NADPH and GSH 
in apigenin-treated H1299 cells were strongly reversed in the 
presence of 20 mM galactose (Fig. 4A). Moreover, galactose 
decreased ROS levels by ~50% (Fig. 4B). Fig. 4C shows that 
galactose increased cell viability by ~40% in apigenin-treated 
H1299 and H460 cells. Consistent with these results, the 
numbers of apoptotic cells were also markedly decreased by 
~20% in the presence of apigenin with galactose supplemented 
cells (Fig. 4D). Fig. 4E shows that apigenin-mediated activa-
tion of caspase-9, -3 and PARP apoptotic pathways (left panel) 
and decreased clonogenic cell survival (right panel) were 
completely blocked by 20 mM galactose in H1299 lung cancer 
cells. Together, these results indicate that galactose confers 
resistance to apigenin-mediated apoptosis by activating 
NADPH production through the pentose phosphate pathway.
Cancer cells expressing high levels of GLUT1 are resistant 
to apigenin-induced apoptosis through metabolic compensa-
tion of glucose utilization. Because apigenin induces cancer 
cell death by suppressing GLUT1 expression and glucose 
utilization in multiple types of cancer cell lines, we examined 
whether GLUT1-overexpressing cancer cells could confer 
resistance to apigenin-induced apoptosis. For this purpose, we 
generated H1299 cell stably expressing a GLUT1 lentiviral 
vector, or an empty vector (Fig. 5A). Fig. 5B shows that, even 
in the presence of apigenin, glucose consumption increased 
dramatically in GLUT1-overexpressing H1299 cells compared 
to cells harboring the empty vector. Furthermore, GLUT1 
overexpression produced high levels of lactate in apigenin-
treated H1299 cells compared to levels of lactate in cells 
carrying the empty vector. To determine whether GLUT1 
overexpression could block apigenin-mediated suppression 
of NADPH and GSH production, we measured intracellular 
NADPH and GSSG levels in GLUT1-overexpressing H1299 
Figure 3. NAC treatment attenuates the apigenin-dependent induction of apoptosis through inhibition of caspase-9, -3 and PARP activation. (A) Apoptosis was 
measured in H1299 and H460 lung cancer cell cultures treated with 10 µM apigenin. Values represent mean ± SD of three independent experiments performed 
in triplicate; *p<0.05. (B) Activation of caspase-9, -3 and PARP was detected by immunoblotting. (C) Cell viability was measured in H1299 and H460 lung 
cancer cell cultures treated with 10 µM apigenin in the absence or presence of NAC. Values represent mean ± SD of three independent experiments performed 
in triplicate; *p<0.05 and #p<0.05. (D) Apoptosis was measured in H1299 and H460 lung cancer cell cultures treated with 10 µM apigenin in the absence or 
presence of NAC. Values represent mean ± SD of three independent experiments performed in triplicate; *p<0.05, #p<0.05.
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cells in the presence or absence of apigenin. Interestingly, 
the effects of apigenin on NADPH and GSH levels were 
significantly rescued by GLUT1 overexpression (Fig. 5C). 
Furthermore, GLUT1 overexpression attenuated the effect of 
apigenin on ROS, resulting in a clear decrease in ROS levels of 
~50% (Fig. 5D). Because increased oxidative stress is a critical 
step for apigenin-mediated apoptosis, we examined whether 
GLUT1-overexpressing cells were resistant to apigenin-
mediated cell death. Fig. 5E shows that 50 µM apigenin was 
required to decrease cell viability in GLUT1-overexpressing 
cells, while 10 µM apigenin was sufficient to decrease cell 
viability in cells harboring the empty vector. Fig. 5F shows that 
30 µM apigenin induced 20% of the cells to undergo apoptosis 
in GLUT1-overexpressing H1299 cells. In contrast, 30 µM 
apigenin induced 50% of cells harboring the empty vector 
to undergo apoptosis. Furthermore, GLUT1 overexpression 
dramatically reversed the apigenin-mediated suppression of 
clonogenic cell survival (Fig. 5G, left panel) and attenuated the 
activation of caspase-9 and caspase-3 in H1299 cells (Fig. 5G, 
right panel). These results suggest that GLUT1 overexpression 
causes resistance to apigenin-mediated apoptosis through 
suppression of metabolic and oxidative stress.
Inhibition of glutamine utilization sensitizes apigenin-
induced apoptosis through exacerbation of metabolic stress. 
In cancer cells, glutamine is a nutrient critical for promotion of 
Figure 4. Galactose supplementation confers resistance to apigenin-induced apoptosis. (A) Intracellular NADPH and GSH levels were measured in H1299 
lung cancer cell cultures treated with 10 µM apigenin in the absence or presence of 20 mM of galactose. Values represent mean ± SD of three independent 
experiments performed in triplicate; *p<0.05, #p<0.05. (B) Intracellular ROS levels. Values represent mean ± SD of three independent experiments performed 
in duplicate; *p<0.05, #p<0.05. (C) Cell viability was measured in H1299 and H460 lung cancer cell cultures treated with 10 µM apigenin in the absence or 
presence of 20 mM of galactose. Values represent mean ± SD of three independent experiments performed in triplicate; *p<0.05, #p<0.05. (D) Apoptosis was 
measured in H1299 and H460 lung cancer cell cultures treated with 10 µM apigenin in the absence or presence of 20 mM of galactose. Values represent mean 
± SD of three independent experiments performed in triplicate; *p<0.05, #p<0.05. (E) Cleaved caspase-9, -3 and PARP were detected by immunoblotting in 
apigenin-treated H1299 lung cancer cells in the absence or presence of 20 mM of galactose. Clonogenic cell survival was evaluated in apigenin-treated H1299 
lung cancer cells in the absence or presence of 20 mM of galactose.
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tumor growth and survival (30,31). Thus, inhibitors targeting 
glutamine utilization have shown potential as anticancer drugs 
(18-20). We therefore hypothesized that inhibition of glutamine 
utilization might sensitize cancer cells to apigenin-mediated 
cell death, and that the mechanism would involve suppression 
of the major pathways of glucose and glutamine metabolism 
Figure 5. GLUT1 overexpression confers resistance to apigenin-induced apoptosis. (A) Ectopically expressed GLUT1 was detected by immunoblotting. 
(B) Glucose consumption and lactate production were measured in apigenin-treated H1299 lung cancer cells harboring either the empty vector or the GLUT1 
expression vector. Values represent mean ± SD of three independent experiments performed in triplicate; *p<0.05, #p<0.05. (C) Intracellular NADPH and 
GSH levels were determined in apigenin-treated H1299 lung cancer cells harboring either the empty vector or the GLUT1 expression vector. Values represent 
mean ± SD of three independent experiments performed in duplicate; *p<0.05, #p<0.05. (D) Intracellular ROS levels. Values represent mean ± SD of three 
independent experiments performed in duplicate; **p<0.01, #p<0.05. (E) Cell viability was determined in apigenin-treated H1299 lung cancer cells harboring 
either the empty vector or the GLUT1 expression vector. Note the dose-dependent effects of apigenin treatment. Values represent mean ± SD of three indepen-
dent experiments performed in duplicate; *p<0.05. (F) Apoptotic cell numbers were determined, after treatment at the indicated concentrations of apigenin, 
in H1299 lung cancer cells harboring either the empty vector or the GLUT1 expression vector. Values represent mean ± SD of three independent experiments 
performed in duplicate; *p<0.05. (G) Clonogenic cell survival was performed after treatment with 10 µM apigenin in H1299 cell cultures harboring either the 
empty vector or the GLUT1 expression vector. The cleaved caspase-9 and caspase-3 proteins were detected by immunoblotting.
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required for tumor growth and survival. In support of this idea, 
Fig. 6A shows that compound 968, a GLS inhibitor, synergized 
with apigenin, resulting in an ~75% reduction of ATP levels in 
H1299 and H460 cells. Because glutamine utilization supports 
NADPH production needed for redox control (31), we addition-
ally examined whether combination treatment of apigenin and 
compound 968 is sufficient to increase severe oxidative stress 
by decreasing NADPH and increasing intracellular ROS levels 
in cancer cells. Here, we found that compound 968 hugely 
decreased NADPH (Fig. 6B) and increased intracellular ROS 
levels (Fig. 6C) in the presence of apigenin. Furthermore, 
apigenin-treated cells, compound 968 exacerbated the 
reduction in cell viability (Fig. 6D), increased the induction 
of apoptosis (Fig. 6E, upper panel), and reduced clonogenic 
cell survival (Fig. 6E, bottom panel). In addition, we used a 
short hairpin RNA (shRNA) to knock down GLS1 expression 
by >70% in H1299 and H460 cell (Fig. 6F). Fig. 6G shows that 
apigenin caused a large decrease in cell viability of ~80% in 
GLS1 knocked-down H1299 and H460 cells. Consistent with 
this, caspase-9 and PARP were more strongly activated in these 
cells (Fig. 6H), suggesting that decreased GLS1 expression or 
activity would make cancer cells more susceptible to apigenin-
mediated apoptosis. Taken together, these results indicate that 
inhibition of glutamine utilization should sensitize lung cancer 
cells to apigenin-mediated apoptosis.
Discussion
In recent years, apigenin, which is abundant in common fruits 
and vegetables, has shown considerable promise for develop-
ment as an anticancer and chemopreventive agent (2,3,6). In 
fact, several recent reports have shown that apigenin is capable 
of selectively suppressing growth and inducing apoptosis in 
cancer cells by affecting the activities of protein tyrosine 
kinases, including epidermal growth factor receptor (EGFR), 
Src tyrosine kinase, phosphatidylinositol 3-kinase (PI3K), 
mitogen-activated protein kinase (MAPK), and hypoxia-
inducible factor-1α (HIF-1α) (32-36). It has been reported that 
apigenin suppresses glucose uptake by a mechanism involving 
decreased GLUT1 expression, leading to increased apoptosis 
and chemosensitivity in pancreatic carcinoma, laryngeal 
carcinoma, and head and neck cancer (22-25). However, 
there is no previous evidence to indicate that a combination 
of apigenin with other inhibitors of cancer metabolism would 
show a synergistic effect in the suppression of cancer growth 
and survival. In this study, we observed that downregulation 
of GLUT1 by apigenin led to suppression of glucose utiliza-
tion through decreased glycolysis and pentose phosphate 
metabolism, thereby suppressing the generation of ATP, 
macromolecules, and NADPH required for cancer cell growth, 
proliferation, and survival. Furthermore, our findings indicate 
Figure 6. Inhibition of glutamine metabolism sensitizes lung cancer cells to apigenin-induced apoptosis. (A) Intracellular ATP levels were determined in 
H1299 and H460 lung cancer cells treated with 10 µM apigenin in the absence or presence of 5 µM compound 968. Values represent mean ± SD of three inde-
pendent experiments performed in duplicate; *p<0.05, **p<0.01. (B) NADPH levels were determined in H1299 and H460 lung cancer cells treated with 10 µM 
apigenin in the absence or presence of 5 µM compound 968. Values represent mean ± SD of three independent experiments performed in triplicate; *p<0.05, 
**p<0.01. (C) Intracellular ROS levels were measured in H1299 and H460 lung cancer cells treated with 10 µM apigenin in the absence or presence of 5 µM 
compound 968. Values represent mean ± SD of three independent experiments performed in duplicate; *p<0.05, **p<0.01. (D) Cell viability was determined in 
H1299 and H460 lung cancer cell cultures treated with 10 µM apigenin in the absence or presence of 5 µM compound 968. Values represent mean ± SD of three 
independent experiments performed in duplicate; *p<0.05, **p<0.01. (E) Apoptotic cell numbers were determined in H1299 and H460 lung cancer cell cultures 
treated with 10 µM apigenin in the absence or presence of 5 µM compound 968. Values represent mean ± SD of three independent experiments performed 
in duplicate; *p<0.05, **p<0.01. (F) GLS1 protein levels in H1299 and H460 cells were determined by immunoblotting. (G) Cell viability was determined in 
H1299 and H460 lung cancer cells expressing either GLS1 shRNA or scrambled shRNA in absence or presence of apigenin. Values represent mean ± SD of 
three independent experiments performed in triplicate; *p<0.05, **p<0.01. (H) Cleaved caspase-9 and PARP were detected by immunoblotting in H1299 and 
H460 lung cancer cells expressing GLS1 shRNA or scrambled shRNA in the absence or presence of apigenin (n=3). Protein levels were quantified by ImageJ.
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that ectopic overexpression of GLUT1, combined with galac-
tose supplementation to enhance PPP-mediated NADPH and 
biomass generation, confers resistance to apigenin-mediated 
apoptosis in several lung cancer cell lines. GLUT1 is upregu-
lated in multiple types of cancer, and is closely correlated with 
cancer grade, radio-resistance, and chemo-resistance (10,37). 
Indeed, several GLUT1 inhibitors, including WZB117 and 
fasentin, have been developed as anticancer drugs (12,13). 
Thus, apigenin treatment might provide a selective anticancer 
strategy, acting through suppression of GLUT1-mediated 
cancer growth and survival.
Growing cancer cells use large amounts of glucose and 
glutamine to meet the bioenergetics and biosynthetic demands 
of increased cell growth and survival (7,8). It is becoming clear 
that altered metabolic pathways in cancer cells, such as aerobic 
glycolysis, fatty acid synthesis, and glutamine utilization are 
closely linked to therapeutic resistance in cancer treatment 
(7,8,26). Therefore, treatment of cancer using combinations 
of chemotherapeutic drugs and selective cancer metabolism 
inhibitors could represent a promising strategy to overcome 
chemoresistance. Indeed, several reports have shown that inhi-
bition of glycolysis enhances the susceptibility of lung cancer, 
multiple myeloma, and breast cancer to apoptosis during treat-
ment with anticancer drugs, such as cisplatin, doxorubicin, and 
trastuzumab (18). Previous reports have shown that GLS inhib-
itors, such as CB-839 and compound 968, can suppress cancer 
growth and survival in vitro and in vivo (20,38). However, these 
studies did not address whether the combined inhibition of 
glucose and glutamine utilization might represent a promising 
strategy for cancer treatment. In this study, we demonstrated 
that the combined suppression of glucose and glutamine utili-
zation, using a combination of apigenin and compound 968, 
markedly decreased cell viability and increased apoptosis in 
lung cancer cells. Thus, our findings suggest that the simulta-
neous inhibition of multiple cancer metabolic pathways may 
provide a promising strategy for cancer treatment.
Mechanistically, increased ROS is involved in apigenin-
induced apoptosis in prostate and colorectal cancer cells 
(3,6). However, the molecular mechanism by which apigenin 
increases intracellular ROS levels is not well understood. 
Because suppression of glucose utilization is reported to 
induce oxidative stress through inhibition of the PPP and 
NADPH generation (27), we hypothesized that apigenin might 
induce oxidative stress by the same mechanism. Indeed, we 
found that apigenin significantly decreased glucose utilization 
through suppression of GLUT1 expression, and consequently 
decreased NADPH production, which led to increased 
ROS levels. In addition, activation of NADPH production by 
galactose supplementation, which can be entered into PPP, 
significantly reversed the apigenin-induced ROS accumula-
tion. These results therefore suggest a possible mechanism by 
which apigenin induces oxidative stress through inhibition of 
glucose utilization and PPP-mediated NADPH production.
In conclusion, the major findings are that: i) apigenin 
decreases glucose utilization, via glycolysis and the PPP, 
through suppression of GLUT1 expression, thereby resulting in 
the inhibition of cancer cell growth and survival; ii) activation 
of glucose utilization and the PPP by GLUT1 overexpression 
and galactose supplementation confer resistance to apigenin-
induced apoptosis by compensating NADPH production, 
which suppresses ROS accumulation; iii) targeting glutamine 
utilization sensitizes lung cancer cells to apigenin-induced 
apoptosis under conditions of severe metabolic stress. These 
results may provide a promising therapeutic strategy for 
cancer treatment.
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